Home / Pharmaceuticals / Neurotrophic Keratitis Market By Treatment (Preservative Free Artificial Tears, Topical Antibiotics, Tarsorraphy, Amniotic Membrane Transplantation, Bandage Contact Lenses, Recombinant Human Nerve Growth Factor) - Growth, Future Prospects And Competitive Landscape, 2019 – 2027

Neurotrophic Keratitis Market By Treatment (Preservative Free Artificial Tears, Topical Antibiotics, Tarsorraphy, Amniotic Membrane Transplantation, Bandage Contact Lenses, Recombinant Human Nerve Growth Factor) - Growth, Future Prospects And Competitive Landscape, 2019 – 2027

Published: Jun 2019 | Report Code: 59723-06-19

Industry Outlook

The neurotrophic keratitis market is set to highlight rapid growth at a compounded annual growth rate (CAGR) of 5.2% during the forecast period from 2019 to 2027. Neurotrophic keratitis is an orphan disease which is primarily caused due to the damage of the fifth cranial nerve from the trigeminal nucleus to the nerve endings preset in the eye corneal region. Traditional therapies are employed to suppress the clinical manifestation occurring in different stages of the disease. Currently RGN-259 developed by ReGenTree, LLC. is in the phase III clinical trial study for the treatment of neurotrophic keratitis.

Market Synopsis

Neurotrophic Keratitis Market

Get a sample copy for more information

"Recent EMA approval of Oxervate and priority review designation approved by the USFDA will popularize the recombinant human nerve growth factor during the forecast period"

Neurotrophic keratitis is a rare degenerative disease which results I loss of corneal sensation and dampens its healing process. The global prevalence rate of neurotrophic keratitis is reported to be 5 per 10,000 individuals. The treatment options adopted for neurotrophic keratitis depends upon the severity and stage of the disease. Artificial tears are prescribed for all the stages due to its ability to provide wetness and lubrication to the corneal surface and ensure cleanliness. Topical antibiotics are majorly prescribed during the stage 2 of the disease for prophylactic treatment of infection. Despite pharmacological treatment and in stage 3 of the disease surgical interventions such as Tarsorraphy and amniotic membrane transplantation is employed to heal corneal ulceration. The recent approval of Oxervate by EMA and priority review designation approved by the USFDA will popularize the utilization of recombinant human nerve growth factor for the treatment of neurotrophic keratitis during the forecast period.

Neurotrophic Keratitis Market

Get a sample copy for more information

"Rising prevalence of neurotrophic keratitis and affordable reimbursement scenario drive the market growth in North America"

North America is presently responsible for 33% market share and is leading the regional segment for neurotrophic keratitis market. According to American Academy of Ophthalmology (AAO), approximately 65,000 people in the United States are suffering with this rare disease. The chief contributing factors accountable for its dominance in regional market are rising prevalence of neurotrophic keratitis and affordable reimbursement scenario pertaining to the medication used for its treatment. Europe trails North America in regional market with a share of 28.5% primarily due to strategic collaboration between government healthcare agencies and academic research institutes for the development of novel drugs for treating neurotrophic keratitis in Europe. The European Medical Agency (EMA) has designated orphan disease status to neurotrophic keratitis and has designated fast track status for its drug development and sale in the region. Asia Pacific holds 16% market share owing to the increasing incidence rate of neurotrophic keratitis in geriatric population and supportive regulatory scenario provided by regional healthcare agencies.

Neurotrophic Keratitis Market

Get a sample copy for more information

Historical & Forecast Period

This research report presents the analysis of each segment from 2017 to 2027 considering 2018 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

The market is segmented by treatment and by geography. 

ATTRIBUTE DETAILS
Research Period  2017-2027
Base Year 2018
Forecast Period  2019-2027
Historical Year  2017
Unit  USD Million
Segmentation

 By Treatment (2017–2027; US$ Mn)
 • Preservative Free Artificial Tears
 • Topical Antibiotics
 • Tarsorraphy
 • Amniotic Membrane Transplantation
 • Bandage Contact Lenses
 • Recombinant Human Nerve Growth Factor

 Geography Segment (2017–2027; US$ Mn)
 • North America (U.S., Canada)
 • Europe (U.K., Germany, Rest of Europe)
 • Asia Pacific (China, Japan, Rest of APAC)
 • Latin America (Brazil, Mexico, Rest of Latin America)
 • Middle East and Africa (GCC, Rest of Middle East and Africa)

Pharmaceutical companies specializing in providing medication for the treatment of neurotrophic keratitis are Allergan, Plc., Abbott Laboratories, Inc., Bausch & Lomb Incorporated, Bayer AG, CooperVision, Dompe farmaceutici S.p.A., Johnson & Johnson, Novartis AG, ReGenTree, LLC., and Walgreens.

Key questions answered in this report

  • Which strategic collaboration, merger and acquisitions are taking place in the neurotrophic keratitis market?
  • Which key players are manufacturing medicines for the treatment of neurotrophic keratitis market?
  • What is the disease etiology of neurotrophic keratitis and medicines prescribed as per the different stages of the disease?
  • What is Oxervate and how will it perform during the forecast period?
  • What will be the market performance of developing regions such as Asia Pacific and Latin America in the neurotrophic keratitis market?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Treatment
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global NK Market Portraiture
2.2. Global NK Market, by Treatment, 2018 (US$ Mn)
2.3. Global NK Market, by Geography, 2018 (US$ Mn)

Chapter 3. Neurotrophic Keratitis (NK) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Analysis: Global NK Market, by Key Players, 2018

Chapter 4. Global Neurotrophic Keratitis (NK) Market, by Treatment
4.1. Overview
4.2. Preservative Free Artificial Tears
4.3. Topical Antibiotics
4.4. Tarsorraphy
4.5. Amniotic Membrane Transplantation
4.6. Bandage Contact Lenses
4.7. Recombinant Human Nerve Growth Factor (Oxervate)
4.8. Pipeline Analysis
4.8.1. Phase III Drug
4.8.1.1. RGN-259

Chapter 5. Global Neurotrophic Keratitis (NK) Market, by Geography
5.1. Overview
5.2. North America NK Market Analysis, 2017 – 2027
5.2.1. North America NK Market, by Treatment, 2017 – 2027 (US$ Mn)
5.2.2. North America NK Market, by Country, 2017 – 2027 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe NK Market Analysis, 2017– 2027
5.3.1. Europe NK Market, by Treatment, 2017 – 2027 (US$ Mn)
5.3.2. Europe NK Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific NK Market Analysis, 2017 – 2027
5.4.1. Asia Pacific NK Market, by Treatment, 2017 – 2027 (US$ Mn)
5.4.2. Asia Pacific NK Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific
5.5. Latin America NK Market Analysis, 2017 – 2027
5.5.1. Latin America NK Market, by Treatment, 2017 – 2027 (US$ Mn)
5.5.2. Latin America NK Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa NK Market Analysis, 2017 – 2027
5.6.1. MEA NK Market, by Treatment, 2017 – 2027 (US$ Mn)
5.6.2. MEA NK Market, by Region, 2017– 2027 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Allergan, Plc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Abbott Laboratories, Inc.
6.3. Bausch & Lomb Incorporated
6.4. Bayer AG
6.5. CooperVision
6.6. Dompe farmaceutici S.p.A.
6.7. Johnson & Johnson
6.8. Novartis AG
6.9. ReGenTree, LLC.
6.10. Walgreens

* Here we are using NK as a short form of Neurotrophic Keratitis

FIG. 1 : Neurotrophic Keratitis (NK) Market: Research Methodology
FIG. 2 : NK: Market Segmentation
FIG. 3 : Global NK Market, by Treatment, 2018 (US$ Mn)
FIG. 4 : Global NK Market, by Geography, 2018 (US$ Mn)
FIG. 5 : Attractive Investment Proposition: by Geography, 2018
FIG. 6 : Competitive Analysis: Global NK Market, by Key Players, 2018
FIG. 7 : Global Preservative Free Artificial Tears Market for NK, 2017 – 2027 (US$ Mn)
FIG. 8 : Global Topical Antibiotics Market for NK, 2017 – 2027 (US$ Mn)
FIG. 9 : Global Tarsorraphy Market for NK, 2017 – 2027 (US$ Mn)
FIG. 10 : Global Amniotic Membrane Transplantation Market for NK, 2017– 2027 (US$ Mn)
FIG. 11 : Global Bandage Contact Lenses Market for NK, 2017 – 2027 (US$ Mn)
FIG. 12 : Global Recombinant Human Nerve Growth Factor Market for NK, 2017 – 2027 (US$ Mn)
FIG. 13 : U.S. NK Market, 2017 – 2027 (US$ Mn)
FIG. 14 : Canada NK Market, 2017 – 2027 (US$ Mn)
FIG. 15 : U.K. NK Market, 2017 – 2027 (US$ Mn)
FIG. 16 : Germany NK Market, 2017 – 2027 (US$ Mn)
FIG. 17 : Rest of Europe NK Market, 2017 – 2027 (US$ Mn)
FIG. 18 : China NK Market, 2017– 2027 (US$ Mn)
FIG. 19 : Japan NK Market, 2017 – 2027 (US$ Mn)
FIG. 20 : Rest of Asia Pacific NK Market, 2017 – 2027 (US$ Mn)
FIG. 21 : Brazil NK Market, 2017 – 2027 (US$ Mn)
FIG. 22 : Mexico NK Market, 2017 – 2027 (US$ Mn)
FIG. 23 : Rest of Latin America NK Market, 2017 – 2027 (US$ Mn)
FIG. 24 : GCC NK Market, 2017 – 2027 (US$ Mn)
FIG. 25 : Rest of Middle East and Africa NK Market, 2017 – 2027 (US$ Mn)

TABLE 1 : Global Neurotrophic Keratitis (NK) Market Portraiture
TABLE 2 : Global NK Market, by Treatment, 2017 – 2027 (US$ Mn)
TABLE 3 : Global NK Market, by Geography, 2017 – 2027 (US$ Mn)
TABLE 4 : North America NK Market, by Treatment, 2017 – 2027 (US$ Mn)
TABLE 5 : North America NK Market, by Country, 2017 – 2027 (US$ Mn)
TABLE 6 : Europe NK Market, by Treatment, 2017 – 2027 (US$ Mn)
TABLE 7 : Europe NK Market, by Country/Region, 2017– 2027 (US$ Mn)
TABLE 8 : Asia Pacific NK Market, by Treatment, 2017 – 2027 (US$ Mn)
TABLE 9 : Asia Pacific NK Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 10 : Latin America NK Market, by Treatment, 2017 – 2027 (US$ Mn)
TABLE 11 : Latin America NK Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 12 : Middle East and Africa NK Market, by Treatment, 2017– 2027 (US$ Mn)
TABLE 13 : Middle East and Africa NK Market, by Region, 2017 – 2027 (US$ Mn)
TABLE 14 : Allergan, Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 15 : Abbott Laboratories, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 16 : Bausch & Lomb Incorporated: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 17 : Bayer AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 18 : CooperVision: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19 : Dompe farmaceutici S.p.A.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20 : Johnson & Johnson: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 : Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 : ReGenTree, LLC.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 : Walgreens: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Our Clients